Newborn Screening Market Expected to Reach $2.0 Billion by 2031

According to a new report published by Allied Market Research, titled, “Newborn Screening Market," The newborn screening market was valued at $1.1 billion in 2021, and is estimated to reach $2.0 billion by 2031, growing at a CAGR of 6.8% from 2022 to 2031.

Newborn screening refers to a series of special tests which includes blood, hearing, and heart screening, done to one- to two-day-old infants, usually before they leave the hospital. This is use to check for any serious health disorders that do not show signs at birth. The tests often scan for genetic and metabolic abnormalities, hearing problems, specific heart problems, and other conditions that can hinder their development. Newborn babies that have health conditions may not exhibit any symptoms at infancy. If left untreated, the baby may develop serious problems, Newborn screening helps with the early diagnosis of these conditions so babies can begin treatment as soon as possible—before the disease even turns serious or so early interventions can be made.

The major driving factors of Newborn Screening Industry include increasing government support for newborn screening and development in screening technology. Furthermore, to high birth rate and increasing incidence of neonatal disease expected to supplement the newborn screening market growth. However, lack of improvement in healthcare infrastructure and limited number of trained professionals are expected to impede the market growth. Conversely, screening of genetic disorders and emerging market such as Brazil, China and India provide significant opportunities to key players in this market due to increase in birth rates and rise in disposable income.

On the basis of product, the consumables segment dominated the market in 2021. This segment is expected to exhibit a prominent growth rate, owing to increasing newborn disease prevalence and increasing newborn screening rate.

On the basis of test type, the blood test segment is expected to dominate the Newborn Screening Market trends and is expected to register a highest CAGR of 7.3% during the forecast period. owing to increase in the usage of DBS (Dry blood spot test) for serological diagnosis of infectious or autoimmune disease and easy and effective diagnosis as compare to other testing methods.

Depending on technology, the tandem mass spectrometry (TMS) segment dominated the Newborn Screening Market size in 2021. This segment is expected to exhibit a prominent growth rate, owing to cost effectiveness, high applicability and technology upgrades.

On the basis of end user, the hospital segment dominated the market in 2021, and is expected to exhibit prominent growth rate of Newborn Screening Market share, owing to rise in disposable income with rise in need for hospitalization for patients, Development in healthcare for infrastructure of hospitals and high-tech equipment in the hospitals further drive the market growth.

Region wise, North America accounted for more than 6.6% of the global market share in 2020, and is expected to remain dominant throughout the forecast period. This was attributed to the availability of newborn screening programs, favorable reimbursement policies and strong market players presence. Asia-Pacific is projected to register the highest CAGR of 7.9% during the forecast period, owing to the high population density, higher birth rate and the soaring prevalence of congenital diseases.

KEY FINDINGS OF THE STUDY.

• Based on product, the consumables held the largest market share in 2021 and is expected to remain dominant during the forecast period.
• Based on test, the blood test segment held the largest share in the global market in 2021
• On the basis of technology, the tandem mass spectrometry (TMS) held the largest market share in 2021 and is expected to remain dominant during the forecast period.
• Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 7.9% during the forecast period.